Paediatric Clinical Neurology
Basic and Clinical Pharmacology, 11th Edition
The most trusted and up-to-date pharmacology text in medicine — completely redesigned to make the learning process even more interesting and efficient
A Doody’s Core Title ESSENTIAL PURCHASE for 2011!
5 Star Doody’s Review!
“This is the most widely used textbook for teaching pharmacology to health professionals. This 11th edition is far superior to any previous editions….The authors’ goals are to provide a complete, authoritative, current, and readable textbook of pharmacology for students in health sciences. Testimony to their success is the widespread use of this work as required textbook for pharmacology courses around the world. This book is used extensively by thousands of medical, pharmacy, podiatry, nursing, and other health professions students to study pharmacology. Likewise, it remains a valuable resource for residents and practicing physicians….I continue to use this book as a required resource for all courses that I teach to medical, nursing, and allied health students. It is authoritative, readable, and supported by numerous learning tools.”–Doody’s Review Service
Organized to reflect the syllabi in Pharmacology courses, Basic & Clinical Pharmacology covers all the important concepts students need to know about the science of pharmacology and its application to clinical practice. It is acknowledged worldwide as the field’s most current, authoritative, and comprehensive textbook. To be as clinically relevant as possible, the book features a strong focus on the choice and use of drugs in patients and the monitoring of their effects. Read More…
Latest News from Pharma Industry:
Abbott reports first-quarter 2014 results
Abbott (NYSE: ABT) has announced financial results for the first quarter ended March 31, 2014. First-quarter 2014 worldwide sales of $5.2 billion increased 0.5 percent on an operational basis and decreased 2.5 percent on a reported basis, including an unfavorable 3.0 percent effect of foreign exchange.
Roche with good start in 2014
Group sales rose 5% in the first quarter, driven by demand for cancer medicines (in particular the HER2 breast cancer franchise, Avastin and MabThera/Rituxan), as well as Actemra/RoActemra for rheumatoid arthritis. Sales of Xeloda, a chemotherapy drug, were lower as the product is now off patent and faces generic competition in the United States and Europe.
Enzyme revealed as promising target to treat asthma and cancer
In experiments with mice, Johns Hopkins Kimmel Cancer Center scientists have identified an enzyme involved in the regulation of immune system T cells that could be a useful target in treating asthma and boosting the effects of certain cancer therapies. In research described online April 6 in Nature Immunology, the investigators show that mice without the enzyme SKG1 were resistant to dust mite-induced asthma.
Virus-fighting genes linked to mutations in cancer
Researchers have found a major piece of genetic evidence that confirms the role of a group of virus-fighting genes in cancer development. Our understanding of the biological processes that cause cancer is limited. UV light and smoking are two well-understood cancer-causing processes. Exposure to either of these processes causes distinguishable patterns of genetic damage, or 'signatures', on the genome that can lead to cancer.
Yeast provides genetic clues on drug response
Why do people respond differently to the same drug? For the first time, researchers have untangled genetic and environmental factors related to drug reactions, bringing us a step closer to predicting how a drug will affect us. Researchers at the University of British Columbia exposed 6,000 strains of yeast to 3,000 drugs. Yeast strains were modified so their response could be measured.